Eli Lilly and Company announced changes to its executive leadership team. Mike Mason, executive vice president and president of Lilly Diabetes and Obesity, will retire from Lilly at the end of 2023 after 34 years with the company. Over the last two decades, Mason has served in the leadership of Lilly’s Neuroscience and Diabetes businesses…
Eli Lilly and Company announced the successful completion of its acquisition of Dermira, Inc. Lilly completed the acquisition of Dermira through the merger of Bald Eagle Acquisition Corporation with and into Dermira, with Dermira surviving the merger as a wholly-owned subsidiary of Lilly. As of the expiration of the tender offer, 40,926,025 shares of Dermira…